February 11, 2020 / 1:37 PM / 6 days ago

BRIEF-Vistagen Announces Positive Preclinical Data Of Av-101 Combined With Probenecid

Feb 11 (Reuters) - VistaGen Therapeutics Inc:

* VISTAGEN THERAPEUTICS ANNOUNCES POSITIVE PRECLINICAL DATA OF AV-101 COMBINED WITH PROBENECID SUGGESTING SUBSTANTIALLY INCREASED BRAIN CONCENTRATION EFFECTS

* VISTAGEN THERAPEUTICS - NEW PRECLINICAL DATA SUGGEST THERE IS A SUBSTANTIALLY INCREASED BRAIN CONCENTRATION OF AV-101 AND ITS ACTIVE METABOLITE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below